ZGN-440 (Beloranib for Subcutaneous Injection), A Novel Methionine Aminopeptidase 2 Inhibitor for Treatment of Obesity: A Randomized Double-Blind Placebo Controlled Dose Escalation Phase 1b Trial to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Initial Weight Loss

Trial Profile

ZGN-440 (Beloranib for Subcutaneous Injection), A Novel Methionine Aminopeptidase 2 Inhibitor for Treatment of Obesity: A Randomized Double-Blind Placebo Controlled Dose Escalation Phase 1b Trial to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Initial Weight Loss

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2012

At a glance

  • Drugs Beloranib (Primary)
  • Indications Obesity
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 13 Nov 2012 Results presented at the 2012 Annual Meeting of the North American Association for the Study of Obesity.
    • 22 Sep 2012 Results were presented at the 30th Annual Scientific Meeting of the Obesity Society according to a Zafgen media release. Results were also reported in the media release.
    • 17 Jul 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top